Startseite/Aktien/GMAB

GMAB

USD

Genmab A/S ADS

$28.975+0.435 (1.524%)

Echtzeitkurs

Healthcare

Biotechnologie

Dänemark

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen

Unternehmensfundamentaldaten

Handelsstatistiken

Marktkennzahlen

Eröffnung

$28.540

Hoch

$29.390

Tief

$28.510

Volumen

2.92M

Unternehmensfundamentaldaten

Marktkapitalisierung

17.8B

Branche

Biotechnologie

Land

Denmark

Handelsstatistiken

Durchschnittliches Volumen

2.00M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $17.235Aktuell $28.975Hoch $33.65

Ähnliche Nachrichten

3. Nov. 2025 · 14:05

BusinessWire

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded clinical profile and potential of epcoritamab for a broader range of

Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting

15. Okt. 2025 · 10:29

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $40 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Genmab with a Buy and maintains $40 price target.

HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $40 Price Target

14. Okt. 2025 · 10:23

GlobeNewswire

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025

Company Announcement Net sales of DARZALEX® in the third quarter of 2025 totaled USD 3,672 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech,